title: Could concomitant radio-chemotherapy improve the outcomes of early-stage node negative anal canal cancer patients? A retrospective analysis of 122 patients.
abstract: One hundred twenty-two early-stage anal canal cancer patients (median age: 69 years) were treated with curative radiotherapy with (70 patients) or without (52 patients) concomitant chemotherapy. Median follow-up was 65 months (range: 4-238). At multivariate analysis, concomitant chemotherapy significantly improved local control (p = .007). Local control significantly influenced all considered endpoints, except the metastases free survival. The global rates of G3-G4 acute and late toxicity were 13.1% and 8.2%, respectively, and they were not increased by concomitant chemotherapy. Finally, concomitant chemotherapy is efficacious and safe in the treatment of T1-2N0 anal canal cancer patients and should be prospectively studied.
authors: Radiotherapy Department, Istituto del Radio di Brescia, University of Brescia , Brescia , Italy , 1.
authors: Berardino
authors: B
authors: De Bari
authors: Laëtitia
authors: L
authors: Lestrade
authors: Pascal
authors: P
authors: Pommier
authors: Marta
authors: M
authors: Maddalo
authors: Michela
authors: M
authors: Buglione
authors: Stefano Maria
authors: SM
authors: Magrini
authors: Christian
authors: C
authors: Carrie
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001005:Anus Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies
keywords: Anal cancer; Early-stage anal cancer; Node negative; Radiochemotherapy; Radiotherapy